CD4 and cranioectodermal dysplasia: Given the central role of gluten-specific T cells in CeD pathogenesis1,2, a therapeutic avenue in CeD could be to block the presentation of gluten peptides to CD4+ T cells by HLA-DQ2.5 with a neutralizing antibody.